Sanjay Nilapwar

Principal Scientist I, Purification Development, BioProcess Development, Operations Science & Technology – Biologics at Abbvie, USA

Speaker

Dr. Sanjay Nilapwar currently works as Principal Scientist and Group Leader within AbbVie Bioresearch Center, Worcester MA. Dr Nilapwar looks after purification process development and CMC related aspects of biological portfolio of AbbVie and includes diverse portfolio of mAbs, Bispecifics, Conjugates and AAVs. He is part of platform large molecule CMC development team and is responsible for transitioning of mAb and AAV molecules from candidate drug to development and manufacturing stage, encompassing early to late-stage purification process development, technology transfer and related CMC aspects including filing IND/BLA. Prior to working with AbbVie, he has worked in Incyte Corporation and Medimmune LLC, where he was involved with process development novel biological, such as bispecific mAbs and site-specific conjugates, stability and analytical assay development and was instrumental in setting up large scale conjugate purification lab within Medimmune. He has more than 14 years of experience in mAbs/conjugates purification development and has published 10 papers and written couple of book chapters. He regularly speaks at bioprocessing conferences and chairs conference session. Dr. Nilapwar has earned his PhD in Molecular Biology and Biophysics from UCL, London on an Astra-Zeneca sponsored studentship and M. Pharm in Pharmaceutical Chemistry from Mumbai University on Government of India sponsored Junior Research Fellowship. He currently serves as reviewer for half a dozen journals and is on editorial/review board for Journals, ADC Review, British Journal of Pharmaceutical Research and Bioprocess International. He is also actively involved in BPDG on Protein A resin reuse in clinical manufacturing, AAV viral clearance and Process characterization workstreams.Dr. Sanjay Nilapwar currently works as Principal Scientist and Group Leader within AbbVie Bioresearch Center, Worcester MA. Dr Nilapwar looks after purification process development and CMC related aspects of biological portfolio of AbbVie and includes diverse portfolio of mAbs, Bispecifics, Conjugates and AAVs. He is part of platform large molecule CMC development team and is responsible for transitioning of mAb and AAV molecules from candidate drug to development and manufacturing stage, encompassing early to late-stage purification process development, technology transfer and related CMC aspects including filing IND/BLA. Prior to working with AbbVie, he has worked in Incyte Corporation and Medimmune LLC, where he was involved with process development novel biological, such as bispecific mAbs and site-specific conjugates, stability and analytical assay development and was instrumental in setting up large scale conjugate purification lab within Medimmune. He has more than 14 years of experience in mAbs/conjugates purification development and has published 10 papers and written couple of book chapters. He regularly speaks at bioprocessing conferences and chairs conference session. Dr. Nilapwar has earned his PhD in Molecular Biology and Biophysics from UCL, London on an Astra-Zeneca sponsored studentship and M. Pharm in Pharmaceutical Chemistry from Mumbai University on Government of India sponsored Junior Research Fellowship. He currently serves as reviewer for half a dozen journals and is on editorial/review board for Journals, ADC Review, British Journal of Pharmaceutical Research and Bioprocess International. He is also actively involved in BPDG on Protein A resin reuse in clinical manufacturing, AAV viral clearance and Process characterization workstreams.